Salicin is a natural COX inhibitor.

Significant down regulation of PGE2, the enzymatic product of COX2, to 76% in lysate and 70% in supernatant is observed with Salicin 10 μM treatment in COLO cells when compare to the COLO control. This is accompanied with a minimal COX1 inhibition to 91% of the CCD control on the genetic level. Treatment with Salicin 1 μM decreases colon cancer cell proliferation rates from 144% to 113% at 24 hours and 187% to 130% at 48 hours, with 10 μM decreasing proliferation rates to 108% at 24 hours and 119% at 48 hours^[1]. The concentrations of TNF-α, IL-1β and IL-6 of LPS-induced cells pretreated with 0.07, 0.14 and 0.28 μM Salicin are significant reduced compare with LPS group^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Salicin (D(-)-Salicin) (35, 70, 140 μM) markedly inhibits the LPS-induced pathological changes. MPO activity in LPS-induced lung tissue is significantly increased compare with control group. However, Salicin (35, 70, 140 μM) markedly inhibits this change. Pretreatment with Salicin inhibits LPS-induced activation of JNK, ERK, p38/MAPK and p65 in a dose-dependent manner^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

286.28

C₁₃H₁₈O₇

138-52-3

水杨苷

Room temperature in continental US; may vary elsewhere.

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

In Vitro: 

DMSO : 150 mg/mL (523.96 mM; Need ultrasonic and warming)

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

• [1]. Jun Yan He, et al. Salicin as a Multipurpose Therapeutic Approach for Colon Cancer.

  [2]. Li Y, et al. D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models. Int Immunopharmacol. 2015 Jun;26(2):286-94.

RAW264.7 mouse macrophage cell line is used in this study. RAW264.7 cells are mechanically scraped and plated at a density of 4×10⁵ cells/mL onto 96-well plates in a 37°C, 5% CO₂ incubator for 1 h. Then the cells are treated with 50 μL Salicin (D(-)-Salicin) of different concentrations (0 to 0.28 μM) for 1 h, followed by stimulation with 50 μL Lipopolysaccharide (LPS) (4 μg/mL). After 18 h, 10 μL CCK-8 is added to each well and continued to incubate for 4 h. Then, the optical density is measured at 450 nm on a microplate reader^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Mice are randomly divided into five groups, each containing three mice: Control, Lipopolysaccharide (LPS) only, LPS+Salicin (D(-)-Salicin) group is injected intraperitoneally with Salicin 35 μM, LPS+Salicin group is injected intraperitoneally with Salicin 70 μM, LPS+Salicin group is injected intraperitoneally with Salicin 140 μM. After 1 h, 10 μg LPS dissolved in 50 μL PBS is instilled intranasally to induce lung injury. Control mice are given 50 μL PBS without LPS. After 12 h LPS treatment, bronchoalveolar lavage fluid (BALF) is collected 3 times through a tracheal cannula with autoclaved PBS. Then, the tissue sample is centrifuged at 3000 rpm, for 10 min at 4°C^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Jun Yan He, et al. Salicin as a Multipurpose Therapeutic Approach for Colon Cancer.

  [2]. Li Y, et al. D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models. Int Immunopharmacol. 2015 Jun;26(2):286-94.